CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance

(2017) Stav Sapoznik et al.   Oncotarget

Molecular Concordance Between Primary Breast Cancer and Matched Metastases

(2016) Anne Bruun Krøigård et al.   Breast Journal

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

(2016) George Au-Yeung et al.   CLINICAL CANCER RESEARCH

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma

(2016) Elisabetta Kuhn et al.   MODERN PATHOLOGY

Punctuated copy number evolution and clonal stasis in triple-negative breast cancer

(2016) Ruli Gao et al.   NATURE GENETICS

Early and multiple origins of metastatic lineages within primary tumors

(2016) Zi-Ming Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

(2015) Jeffrey S. Ross et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

(2015) Andrew Tutt et al.   CANCER RESEARCH

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors

(2015) Nawal Bendris et al.   CELL CYCLE

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

(2015) Zahi Mitri et al.   INVESTIGATIONAL NEW DRUGS

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

(2015) Lucy R Yates et al.   NATURE MEDICINE

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

(2015) Liu Yang et al.   Oncotarget

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

(2014) F. Rothé et al.   ANNALS OF ONCOLOGY

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

(2014) F. Meric-Bernstam et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

(2014) Eliezer M Van Allen et al.   NATURE MEDICINE

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

(2013) A. M. Karst et al.   CANCER RESEARCH

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

DGIdb: mining the druggable genome

(2013) Malachi Griffith et al.   NATURE METHODS

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

(2012) Karina H. Gravgaard et al.   BREAST CANCER RESEARCH AND TREATMENT

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation

(2012) Davis J. McCarthy et al.   NUCLEIC ACIDS RESEARCH

Detection of Long Non-Coding RNA in Archival Tissue: Correlation with Polycomb Protein Expression in Primary and Metastatic Breast Carcinoma

(2012) Karen M. Chisholm et al.   PLoS One

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

(2011) Naoki Niikura et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

(2009) C. Liedtke et al.   ANNALS OF ONCOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation

(2009) N. A. Delk et al.   CANCER RESEARCH

A gene expression signature that defines breast cancer metastases

(2009) Rachel E. Ellsworth et al.   CLINICAL & EXPERIMENTAL METASTASIS